Last reviewed · How we verify
NCT05236569
Effectiveness and Safety of Intradermal Tranexamic Acid Injection as An Adjunctive Treatment for Melasma in Skin Type IV - V
NA trial testing Tranexamic acid injection in Melasma in 34 participants. Completed in 31 May 2021.
31 May 2021
Quick facts
| Lead sponsor | Indonesia University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 1 February 2021 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 May 2021 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Tranexamic acid injection — full drug profile →
- Injection Water
Conditions studied
- Melasma — all drugs for Melasma →
Sponsor
Indonesia University
Who can join
Adults 18 to 60, female only, with Melasma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A double-blind, randomized, split-face controlled trial of 34 female patients with melasma was conducted. All subject were randomized to receive either intradermal tranexamic acid or placebo injection on the right or the left side of their face.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05236569
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tranexamic acid injection
Trials testing the same drug.
- NCT04387305 — Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study · Phase 3 · not yet recruiting
- NCT06604325 — Prophylactic Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery. · NA · recruiting
- NCT06010368 — Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section · Phase 3 · not yet recruiting
- NCT06509256 — Different Methods of Tranexamic Acid Application in Controlling Peri Operative Bleeding in Gynecomastia Surgery · EARLY_PHASE1 · not yet recruiting
- NCT06522984 — Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid · NA · recruiting
Other recruiting trials for Melasma
Currently open trials in the same condition.
- NCT06845540 — Oral Metformin for Treating Melasma in Latin American Women · Phase 1, PHASE2 · recruiting
- NCT06644157 — Treatment and Prevention of Melasma Relapses by Using 1064nm 650 Microsecond Laser · NA · active not recruiting
- NCT07034560 — Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma · Phase 4 · active not recruiting
- NCT06516419 — Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy · NA · recruiting
- NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
Other Indonesia University trials
Trials by the same sponsor.
- NCT07137130 — Secretome TGF Beta 3 · NA · not yet recruiting
- NCT07420335 — Preoperative Shoulder Exercises and Postoperative Inflammation, Pain, and Function After Modified Radical Mastectomy · NA · not yet recruiting
- NCT07278284 — The Effectiveness of Press Needle Acupuncture on Preoperative Anxiety in Tympanoplasty and Mastoidectomy · NA · recruiting
- NCT07337187 — Effect of Thread-Embedding Acupuncture at EX-B2 on Pain and Quality of Life in Chronic Low Back Pain · NA · not yet recruiting
- NCT07242001 — Laser Acupuncture for Otitis Media With Effusion in Children · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05236569 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indonesia University
- Last refreshed: 11 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05236569.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing